Stay updated on BMS-986205 Combo with Nivolumab in Melanoma Clinical Trial

Sign up to get notified when there's something new on the BMS-986205 Combo with Nivolumab in Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the BMS-986205 Combo with Nivolumab in Melanoma Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the effectiveness comparison between BMS-986205 combined with nivolumab and nivolumab alone in treating advanced Melanoma that has spread or is inoperable.
    Difference
    0.1%
    Check dated 2024-06-06T14:35:19.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying that researchers look for individuals who meet certain health conditions or prior treatments. Additionally, it now provides a link for more information on Bristol-Myers Squibb Clinical Trial participation and specifies inclusion criteria such as age and health status.
    Difference
    12%
    Check dated 2024-05-22T21:30:03.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:55:10.000Z thumbnail image

Stay in the know with updates to BMS-986205 Combo with Nivolumab in Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the BMS-986205 Combo with Nivolumab in Melanoma Clinical Trial page.